TWI282337B - Substituted chromone compounds,the compositions comprising the said compounds, and the use of said compounds for treating disorders associated with KSP kinesin activity - Google Patents

Substituted chromone compounds,the compositions comprising the said compounds, and the use of said compounds for treating disorders associated with KSP kinesin activity Download PDF

Info

Publication number
TWI282337B
TWI282337B TW092108728A TW92108728A TWI282337B TW I282337 B TWI282337 B TW I282337B TW 092108728 A TW092108728 A TW 092108728A TW 92108728 A TW92108728 A TW 92108728A TW I282337 B TWI282337 B TW I282337B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
optionally substituted
compound
hydrogen
Prior art date
Application number
TW092108728A
Other languages
English (en)
Chinese (zh)
Other versions
TW200408634A (en
Inventor
Andrew Mcdonald
Gustave Bergnes
Bainian Feng
David J Morgans Jr
Steven David Knight
Original Assignee
Cytokinetics Inc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc, Smithkline Beecham Corp filed Critical Cytokinetics Inc
Publication of TW200408634A publication Critical patent/TW200408634A/zh
Application granted granted Critical
Publication of TWI282337B publication Critical patent/TWI282337B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
TW092108728A 2002-04-17 2003-04-15 Substituted chromone compounds,the compositions comprising the said compounds, and the use of said compounds for treating disorders associated with KSP kinesin activity TWI282337B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37345402P 2002-04-17 2002-04-17
US41068202P 2002-09-13 2002-09-13

Publications (2)

Publication Number Publication Date
TW200408634A TW200408634A (en) 2004-06-01
TWI282337B true TWI282337B (en) 2007-06-11

Family

ID=29254526

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092108728A TWI282337B (en) 2002-04-17 2003-04-15 Substituted chromone compounds,the compositions comprising the said compounds, and the use of said compounds for treating disorders associated with KSP kinesin activity

Country Status (21)

Country Link
US (7) US6924376B2 (cg-RX-API-DMAC10.html)
EP (1) EP1511734B1 (cg-RX-API-DMAC10.html)
JP (1) JP4664597B2 (cg-RX-API-DMAC10.html)
KR (1) KR101052816B1 (cg-RX-API-DMAC10.html)
CN (1) CN100381437C (cg-RX-API-DMAC10.html)
AR (1) AR039419A1 (cg-RX-API-DMAC10.html)
AT (1) ATE471931T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003234733B2 (cg-RX-API-DMAC10.html)
BR (1) BR0309278A (cg-RX-API-DMAC10.html)
CA (1) CA2482041C (cg-RX-API-DMAC10.html)
DE (1) DE60333094D1 (cg-RX-API-DMAC10.html)
DK (1) DK1511734T3 (cg-RX-API-DMAC10.html)
IL (2) IL164581A (cg-RX-API-DMAC10.html)
MX (1) MXPA04010240A (cg-RX-API-DMAC10.html)
MY (1) MY140169A (cg-RX-API-DMAC10.html)
NO (1) NO330433B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ536190A (cg-RX-API-DMAC10.html)
PL (1) PL211300B1 (cg-RX-API-DMAC10.html)
RU (1) RU2308454C9 (cg-RX-API-DMAC10.html)
TW (1) TWI282337B (cg-RX-API-DMAC10.html)
WO (1) WO2003088903A2 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4664597B2 (ja) 2002-04-17 2011-04-06 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
ATE423110T1 (de) 2002-07-17 2009-03-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
WO2004024086A2 (en) * 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
PT1601673E (pt) * 2003-03-07 2009-07-29 Astrazeneca Ab Heterociclos fundidos e suas utilizações
JP2007507539A (ja) * 2003-10-06 2007-03-29 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
WO2005087747A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
JP2007527917A (ja) * 2004-03-08 2007-10-04 ワイス イオンチャンネルモジュレーター
DE602005008953D1 (de) * 2004-05-21 2008-09-25 Novartis Vaccines & Diagnostic Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
US20070287703A1 (en) * 2004-07-22 2007-12-13 Astrazeneca Ab Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer
KR20070046175A (ko) * 2004-08-18 2007-05-02 아스트라제네카 아베 선택된 융합 복소환 및 이의 용도
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
CN101027309B (zh) 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
US20090221488A1 (en) * 2005-12-08 2009-09-03 Wood Kenneth W Certain Compositions and Methods of Treatment
US20090093641A1 (en) * 2006-03-13 2009-04-09 University Of Florida Research Foundation, Inc. Synthesis of Pentafluorosulfanyl (SF5)-Substituted Heterocycles and Alkynes
WO2007134183A2 (en) * 2006-05-13 2007-11-22 Advanced Technology Materials, Inc. Chemical reagent delivery system utilizing ionic liquid storage medium
GEP20125415B (en) 2007-01-05 2012-03-12 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
KR102263079B1 (ko) * 2009-11-05 2021-06-10 리젠 파마슈티컬스 소시에떼 아노님 신규한 벤조피란 키나제 조절제
LT2496567T (lt) * 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
PT2705029T (pt) * 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
PT2870157T (pt) 2012-07-04 2017-11-27 Rhizen Pharmaceuticals S A Inibidores seletivos de delta pi3k
RU2015127822A (ru) 2012-12-13 2017-01-16 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы энхансера гомолога 2 белка zeste
CA2917463A1 (en) 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2017015221A1 (en) * 2015-07-23 2017-01-26 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
AU2017218889A1 (en) 2016-02-09 2018-08-30 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
CN111991389B (zh) * 2020-09-17 2021-11-23 陕西科技大学 Sb-743921用于制备抗真菌药物的用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169159A (en) * 1875-10-26 Improvement in corsets
US55054A (en) * 1866-05-29 Improvement in lamp-chimneys
US116400A (en) * 1871-06-27 Improvement in heels for boots and shoes
GB728767A (en) * 1951-10-12 1955-04-27 Wander Ag Dr A 2-substituted chromone compounds, and a method of making same
NL84159C (cg-RX-API-DMAC10.html) 1952-06-30
DE3063585D1 (en) * 1979-05-19 1983-07-07 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
DE3177130D1 (de) 1980-08-30 1990-01-11 Hoechst Ag Aminosaeurederivate, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung.
US4434296A (en) 1982-05-17 1984-02-28 The Upjohn Company Process for preparing intermediates for antiatherosclerotic compounds
US4459420A (en) 1982-05-17 1984-07-10 The Upjohn Company Pyrogallol synthesis of anti-atherogenic furochromones
US4434295A (en) 1982-05-17 1984-02-28 The Upjohn Company Anti-atherosclerotic 6,7-dihydro-7,7-disubstituted-khellin analogs
US4482558A (en) 1982-06-18 1984-11-13 Pfizer Inc. Antifungal amide and urea derivatives of (3-amino-2-aryl-2-hydroxyprop-1-yl)-1H-1,2,4-triazoles
JPS62201882A (ja) 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
IN164232B (cg-RX-API-DMAC10.html) 1986-04-11 1989-02-04 Hoechst India
IL85554A0 (en) 1987-03-02 1988-08-31 Takeda Chemical Industries Ltd Chromone derivatives
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
MX13485A (es) * 1987-10-19 1993-05-01 Pfizer Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
IL89840A (en) 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them
US5180717A (en) 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5304548A (en) 1988-08-16 1994-04-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
DE3836676A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
EP0459983A1 (en) * 1988-12-21 1991-12-11 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5082849A (en) 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
US4977162A (en) 1989-07-13 1990-12-11 Rorer Pharmaceutical Corporation Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
US5215989A (en) 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
ATE158288T1 (de) 1990-06-20 1997-10-15 Upjohn Co Antiatherosklerotische und antithrombotische 1- benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on- derivate
CA2087423A1 (en) 1990-07-25 1992-01-26 Tatsuki Shiota Benzopyran derivative, process for producing the same and pharmaceutical composition containing the same
CA2067167A1 (en) 1990-09-28 1992-03-29 Tokuo Matuzaki Method of producing carbonic acid diester
WO1992006086A1 (en) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
JPH05301813A (ja) 1991-10-15 1993-11-16 Kao Corp 皮膚外用剤
EP0623608B1 (en) 1992-01-24 2001-05-30 Teijin Limited Benzopyran derivative, production thereof, and pharmaceutical preparation containing the same as active ingredient
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
US5605896A (en) 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
FR2693196B1 (fr) 1992-07-03 1994-12-23 Lipha Dérivés de benzopyranone ou de benzothiopyranone, procédé de préparation et composition pharmaceutique les contenant.
JP2579303Y2 (ja) * 1992-08-14 1998-08-27 株式会社共立 バリカン形刈払機
CA2184002A1 (en) 1994-02-23 1995-08-31 Jeffrey M. Blaney Method and compositions for increasing the serum half-life of pharmacologically active agents
EP0764159B1 (en) 1994-06-10 2000-08-09 Smithkline Beecham Plc C -4 amide substituted compounds and their use as therapeutic agents
US5607928A (en) 1994-08-05 1997-03-04 Zeneca Limited Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives
GB9417969D0 (en) 1994-09-07 1994-10-26 King S College London Alkaloids and derivatives thereof
US5602171A (en) 1995-06-07 1997-02-11 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
WO1997014419A1 (en) 1995-10-20 1997-04-24 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
NL1003520C2 (nl) 1996-07-05 1998-01-07 Stork Amsterdam Sterilisatie-inrichting en werkwijze voor het steriliseren van voorwerpen.
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
JPH10273467A (ja) * 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
US6028088A (en) 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
US6087385A (en) 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
DE19858341A1 (de) * 1998-12-17 2000-06-21 Merck Patent Gmbh Chromanderivate
US6399633B1 (en) * 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
US6559160B1 (en) 1999-08-27 2003-05-06 Chemocentryx, Inc. Compounds and methods for modulating cxcr3 function
GB9920910D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel chalcones
GB9920912D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
DE60017157T2 (de) 1999-09-16 2005-12-22 Curis, Inc., Cambridge Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
JP2003531899A (ja) * 2000-05-03 2003-10-28 エルジー ライフ サイエンス リミテッド ３−ヒドロキシクロメン−４−オン構造を有するｃｄｋ阻害剤
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DE10036003A1 (de) 2000-07-25 2002-02-14 Aventis Cropscience Gmbh Herbizide Mittel
US6903121B1 (en) 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
JP2002322169A (ja) 2001-02-21 2002-11-08 Sankyo Co Ltd クロメン誘導体
EA007339B1 (ru) 2001-07-27 2006-08-25 Кьюэрис, Инк. Медиаторы путей передачи сигналов генами hedgehog, содержащие их композиции и способы применения указанных веществ
SE0103648D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
JP4467979B2 (ja) 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
CA2467916A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003050122A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
EP1492487B1 (en) 2002-03-08 2009-11-11 Merck & Co., Inc. Mitotic kinesin inhibitors
JP4664597B2 (ja) 2002-04-17 2011-04-06 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2005530806A (ja) 2002-05-23 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
IL165624A0 (en) 2002-06-14 2006-01-15 Merck & Co Inc Mitotic kinesin inhibitors
AU2003276005B2 (en) 2002-06-14 2009-01-15 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
AU2003247891A1 (en) 2002-07-08 2004-01-23 Merck & Co., Inc. Mitotic kinesin binding site
ATE423110T1 (de) 2002-07-17 2009-03-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
AU2003249534A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2004024086A2 (en) 2002-09-13 2004-03-25 Cytokinetics, Inc. Compounds, compositions and methods
JP2007507539A (ja) 2003-10-06 2007-03-29 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
JP4502322B2 (ja) 2004-11-08 2010-07-14 Ａｇｃテクノグラス株式会社 ガラス管の曲げ加工方法およびその成形用金型

Also Published As

Publication number Publication date
CA2482041C (en) 2012-06-05
KR20050036908A (ko) 2005-04-20
US8633236B2 (en) 2014-01-21
US8119678B2 (en) 2012-02-21
US20040082638A1 (en) 2004-04-29
EP1511734A2 (en) 2005-03-09
CA2482041A1 (en) 2003-10-30
US20110230550A1 (en) 2011-09-22
RU2308454C9 (ru) 2008-05-10
MY140169A (en) 2009-11-30
JP2005523312A (ja) 2005-08-04
RU2004133325A (ru) 2005-10-27
RU2308454C2 (ru) 2007-10-20
BR0309278A (pt) 2005-04-26
AR039419A1 (es) 2005-02-16
CN100381437C (zh) 2008-04-16
IL188954A (en) 2011-02-28
IL164581A (en) 2009-11-18
TW200408634A (en) 2004-06-01
ATE471931T1 (de) 2010-07-15
AU2003234733B2 (en) 2009-01-29
NO330433B1 (no) 2011-04-11
US20090005580A1 (en) 2009-01-01
US7919524B2 (en) 2011-04-05
EP1511734A4 (en) 2006-05-10
KR101052816B1 (ko) 2011-07-29
US7491746B2 (en) 2009-02-17
PL211300B1 (pl) 2012-05-31
PL373577A1 (en) 2005-09-05
US20100105767A1 (en) 2010-04-29
NZ536190A (en) 2007-08-31
DE60333094D1 (de) 2010-08-05
US7629477B2 (en) 2009-12-08
MXPA04010240A (es) 2005-06-08
IL164581A0 (en) 2005-12-18
HK1070656A1 (en) 2005-06-24
AU2003234733A1 (en) 2003-11-03
WO2003088903A2 (en) 2003-10-30
WO2003088903A3 (en) 2004-09-30
CN1662508A (zh) 2005-08-31
US6924376B2 (en) 2005-08-02
DK1511734T3 (da) 2010-08-02
NO20044662L (no) 2005-01-14
US20120209012A1 (en) 2012-08-16
US20060020008A1 (en) 2006-01-26
US20130053436A1 (en) 2013-02-28
US8329928B2 (en) 2012-12-11
EP1511734B1 (en) 2010-06-23
JP4664597B2 (ja) 2011-04-06

Similar Documents

Publication Publication Date Title
TW200408634A (en) Compounds, compositions and methods
CN100491358C (zh) 嘧啶酮类化合物、组合物及方法
Sharma et al. Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents
US9828342B2 (en) Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof
KR101586112B1 (ko) 카바졸 화합물 및 이 화합물의 치료학적 용도
US10640512B2 (en) Imidazopyrazinamine phenyl derivative and use thereof
RU2140417C1 (ru) Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
TW201028386A (en) Novel bicyclic heterocyclic compound
JP2005538062A (ja) 化合物、組成物、および方法
CN102557982A (zh) 某些化学品、组合物及方法
KR101890442B1 (ko) Ｐ2ｘ4 수용체 길항제
KR20090091306A (ko) 암, 염증 및 바이러스 감염 치료용 ｃｄｋ 억제제로서의 헤테로아릴-헤테로아릴 화합물
EA021150B1 (ru) Производные имидазолидина в качестве ингибиторов глутаминилциклазы
JP2022527925A (ja) 芳香族アミン系化合物と、該化合物のａｒおよびｂｒｄ４二重阻害剤ならびに調節剤の製造における使用
TW200524878A (en) Gabanergic modulators
EP2617717B1 (en) P2x4 receptor antagonist
MX2015002310A (es) Nuevas amidas de fenil-piridina/pirazina para el tratamiento de cancer.
JP2006501306A (ja) 化合物、組成物および方法
TW200418818A (en) Compounds, compositions, and methods
MX2011003516A (es) Un dispositivo para la administracion de analgesicos liquidos.
AU2014366436B2 (en) Fluorophenyl pyrazol compounds
WO2014001278A1 (en) A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CN111432820A (zh) 异染色质基因阻抑抑制剂
WO2022002131A1 (zh) 5-((1,2,3,4-四氢异喹啉-7-基)氨基)吡啶-2(1h)-酮衍生物及其应用
WO2022237782A1 (zh) 酰胺衍生物及其应用

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees